THE VALUE OF MEASUREMENT OF RAS ONCOGENES AND NUCLEAR-DNA ANALYSIS IN THE DIAGNOSIS OF HURTHLE CELL TUMORS OF THE THYROID

被引:17
|
作者
SCHARK, C
FULTON, N
YASHIRO, T
STANISLAV, G
JACOBY, R
STRAUS, FH
DYTCH, H
BIBBO, M
KAPLAN, EL
机构
[1] UNIV CHICAGO,PRITZKER SCH MED,DEPT SURG,MC 5031,5841 S MARYLAND AVE,CHICAGO,IL 60637
[2] UNIV CHICAGO,PRITZKER SCH MED,DEPT MED,CHICAGO,IL 60637
[3] UNIV CHICAGO,PRITZKER SCH MED,DEPT PATHOL,CHICAGO,IL 60637
[4] UNIV CHICAGO,PRITZKER SCH MED,DEPT CYTOPATHOL,CHICAGO,IL 60637
关键词
D O I
10.1007/BF02067375
中图分类号
R61 [外科手术学];
学科分类号
摘要
Hurthle cell tumors (HCT) remain difficult to treat because some which appear non-malignant on light microscopy later metastasize. In order to improve diagnostic accuracy, the value of ras mutations and nuclear DNA analysis was determined in 65 patients with HCT. Rapid nuclear DNA cytometry (MicroTICAS system) was performed. Mutations of H-ras, K-ras, and N-ras genes were analyzed by oligonucleotide probe hybridizations to polymerase chain reaction (PCR) amplified DNA. HCT were classified by light microscopy as benign (n = 22), intermediate (n = 30), and malignant (n = 13). After a mean follow-up of 7 years, 1 (4.5%) of 22 benign tumors and 4 (13%) of 30 intermediate tumors had metastasized, leading to tumor death in 3 of these 5 patients. Six of the 13 cancers diagnosed by light microscopy also resulted in tumor-related deaths. Aneuploidy was found in 83% of all Hurthle cell cancers, including 3 (60%) of the 5 cancers not diagnosed microscopically. However, 49% of non-malignant HCT also demonstrated aneuploidy. A nuclear area of less than 55 square microns was found in 83% of all Hurthle cell cancers and in 100% of those cancers not diagnosed by light microscopy. However, 47% of non-malignant HCT also demonstrated a "small" nuclear area. Aneuploidy correctly identified 8 of 9 cancers that resulted in tumor death and each of 3 other tumors that developed metastases. However, 1 patient with a diploid tumor died of metastatic cancer. A nuclear area of less than 55 square microns identified each cancer that resulted in a tumor death. Ras mutations were found in 9 (14%) of 65 Hurthle cell tumors. Only N-ras mutations were found, and 8 of 9 were N-ras, codon 61. Twenty-two percent of Hurthle cell cancers and 11% of non-malignant HCT exhibited ras mutations (p = N.S.) Ras mutations were found in 2 (40%) of 5 cancers which were not recognized microscopically. Of 4 cancers which exhibited ras mutations, 2 (50%) resulted in tumor death. Of 14 cancers that were ras negative, 7 (50%) resulted in death from tumor. We conclude that nuclear DNA cytometric studies are not useful in separating bening from malignant Hurthle cell neoplasms. However, aneuploidy and a nuclear area less than 55 square microns clearly demonstrate those cancers that are likely to act in an aggressive manner and result in tumor death. It should be noted, however, that one patient with a diploid cancer died of metastatic Hurthle cell cancer. Finally, the presence of ras mutations has limited usefulness as a prognostic factor.
引用
收藏
页码:745 / 752
页数:8
相关论文
共 50 条
  • [41] THE RELATIONSHIP BETWEEN NUCLEAR-DNA CONTENT IN SALIVARY-GLAND TUMORS AND PROGNOSIS - COMPARISON OF MUCOEPIDERMOID TUMORS AND ACINIC CELL TUMORS
    HAMPER, K
    CASELITZ, J
    ARPS, H
    ASKENSTEN, U
    AUER, G
    SEIFERT, G
    ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 1989, 246 (05): : 328 - 332
  • [42] Measurement of DNA topoisomerase IIα expression differentiates benign from malignant Hurthle cell neoplasms of the thyroid.
    Faquin, WC
    Pitman, MB
    Barcus, ME
    Nasser, SM
    Pilch, BZ
    Glyptis, T
    Powers, CN
    MODERN PATHOLOGY, 2001, 14 (01) : 75A - 75A
  • [43] GRADING OF BONE-TUMORS BY ANALYSIS OF NUCLEAR-DNA CONTENT USING FLOW-CYTOMETRY
    MANKIN, HJ
    CONNOR, JF
    SCHILLER, AL
    PERLMUTTER, N
    ALHO, A
    MCGUIRE, M
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1985, 67A (03): : 404 - 413
  • [44] Measurement of DNA topoisomerase IIα expression differentiates benign from malignant Hurthle cell neoplasms of the thyroid.
    Faquin, WC
    Pitman, MB
    Barcus, ME
    Nasser, SM
    Pilch, BZ
    Glyptis, T
    Powers, CN
    LABORATORY INVESTIGATION, 2001, 81 (01) : 75A - 75A
  • [45] THE RELATIONSHIPS BETWEEN THE GA-67 UPTAKE AND NUCLEAR-DNA FEULGEN CONTENT IN THYROID-TUMORS - CONCISE COMMUNICATION
    HIGASHI, T
    WATANABE, Y
    YAMAGUCHI, M
    HISADA, T
    MIMURA, T
    ITO, K
    ALLISON, JR
    JOURNAL OF NUCLEAR MEDICINE, 1982, 23 (11) : 988 - 992
  • [46] ADENOCARCINOMA AND MIXED CARCINOMA OF THE UTERINE CERVIX .2. PROGNOSTIC VALUE OF NUCLEAR-DNA ANALYSIS
    FU, YS
    REAGAN, JW
    FU, AS
    JANIGA, KE
    CANCER, 1982, 49 (12) : 2571 - 2577
  • [47] DEGREE OF MALIGNANCY OF THYMIC EPITHELIAL TUMORS IN TERMS OF NUCLEAR-DNA CONTENT AND NUCLEAR-AREA - AN ANALYSIS OF 39 CASES
    ASAMURA, H
    NAKAJIMA, T
    MUKAI, K
    NOGUCHI, M
    SHIMOSATO, Y
    AMERICAN JOURNAL OF PATHOLOGY, 1988, 133 (03): : 615 - 622
  • [48] FLOW CYTOMETRIC ANALYSIS OF NUCLEAR-DNA CONTENT OF DUCT CELL-CARCINOMA OF THE PANCREAS
    YOSHIMURA, T
    MANABE, T
    IMAMURA, T
    IMANISHI, K
    OHSHIO, G
    YAMABE, H
    KITAMURA, O
    MATSUMOTO, M
    OGASAHARA, K
    TAKASAN, H
    TOBE, T
    CANCER, 1992, 70 (05) : 1069 - 1074
  • [49] ANALYSIS OF NUCLEAR AND MITOCHONDRIAL-DNA ALTERATIONS IN THYROID AND RENAL ONCOCYTIC TUMORS
    TALLINI, G
    LADANYI, M
    ROSAI, J
    JHANWAR, SC
    CYTOGENETICS AND CELL GENETICS, 1994, 66 (04): : 253 - 259
  • [50] PROGNOSTIC VALUE OF THE COMBINED ASSESSMENT OF PROLIFERATING CELL NUCLEAR ANTIGEN IMMUNOSTAINING AND NUCLEAR-DNA CONTENT IN INVASIVE HUMAN MAMMARY CARCINOMAS
    SCHIMMELPENNING, H
    ERIKSSON, ET
    FRANZEN, B
    ZETTERBERG, A
    AUER, GU
    VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1993, 423 (04) : 273 - 279